The most important step in achieving regulatory approval for Bactiguard’s BIP Foley catheters on the Chinese market has now been achieved. CMDE yesterday informed that it will approve BIP Foley catheters. CMDE is the division within the China Food and Drug Administration (CFDA) responsible for technical and clinical review, which includes product testing and expert review. Upon receipt of the dossiers from CMDE, CFDA will pursue an administrative examination of the manufacturing file and decide on final product approval.

”This approval is a major milestone for Bactiguard and has the potential to open up one of the largest and fastest growing markets in the world. The Chinese Foley market is estimated to 50-70 million units annually. The decision by CMDE means that Bactiguard’s technology has received regulatory clearance in China. This also paves the way for Bactiguard’s coming product approval applications for endotracheal tubes (BIP ETT) and central venous catheters (BIP CVC). From a value perspective these products have an even greater potential than the Foley catheters,” says Bactiguard’s CEO Johan Rugfelt.

In 2011, Bactiguard signed a distribution agreement with Jian An Pharmaceutical, which has more than 2 000 sales representatives and 5 000 hospitals as their customers in China.

“Bactiguard has a unique and clinically proven solution in preventing healthcare associated infections and we believe it has great potential on the Chinese market,” says Jian An’s CEO, Zhangyi Zhan.

“Jian An has the ambition to achieve a remarkable share of the Chinese Foley market within the coming few years. Hence, we are looking forward to receiving the final regulatory approval and we have started planning for commencement of sales to Chinese hospitals. With the CMDE clearance, Bactiguard has – during the past 12 months – received green light in the major BRIC countries India, Brazil and China. Therefore, we are now very well positioned to execute on our expansion plans.” Johan Rugfelt concludes.

Healthcare associated infections (HAI) are a global problem and the third largest cause of death in the western world. In China, the numbers are also significant. Urinary tract infections account for close to one third of HAI in the western world. Bactiguard’s technology has been tested in 37 clinical studies in eight countries, on more than 100 000 patients. On average, a 39 percent reduction in catheter related infections has been proven, and up to 60 percent in several major clinical studies. Moreover, more than 130 million patients have been treated with Bactiguard-coated products, with no reported negative side effects.

Bactiguard Holding AB (publ) is required to disclose the above information under the provisions of the Securities Market Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 8:35 AM CET on 5 June 2014.

For further information, please contact:

Johan Rugfelt – CEO
johan.rugfelt@bactiguard.se
+46 708 724 739

Cecilia Edström – Director of Communications
cecilia.edstrom@bactiguard.se
+46 722 262 328